Cinqair

Chemical Namereslizumab
Dosage FormInjection (intravenous; 100 mg/10 mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyTeva Respiratory LLC
Approval Year2016

Indication

  • For add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cinqair (reslizumab) Prescribing Information 2020Teva Respiratory, LLC, West Chester, PA